



ASX Announcement

19 July 2021



AnteoTech Signs Australian Distribution Agreement for EuGeni

Highlights

- ❖ AnteoTech secures EuGeni Distribution Agreement with Abacus dx and its New Zealand operating company.
- ❖ Abacus dx to become exclusive distributor in Australia, New Zealand and Pacific Islands.
- ❖ Agreement comes into effect beginning Q4 2021 to align with anticipated TGA registration.

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to advise that it has signed a Distribution Agreement (Agreement) with Abacus dx Pty Ltd (Abacus) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT)¹.

In anticipation of Therapeutic Goods Administration (TGA) registration in Q4, AnteoTech will commence distributor training and business development activities with Abacus as the companies work towards building a customer base in the public and private healthcare and screening markets. With the assistance of AnteoTech, Abacus will be taking the lead on domestic direct marketing activities.

Abacus dx is a distributor of diagnostic pathology, medical research, and innovative laboratory equipment solutions to a range of healthcare practitioners. Its customers include private and public laboratories, blood donor centres as well as university research departments.

As previously announced², AnteoTech has pulled forward its annual ISO13485 compliance audit together with enhanced QMS and MDSAP accreditation to allow for TGA submission for the EuGeni platform in Australia. AnteoTech's TGA submission is targeted for September, the timing of which is dependent on the receipt of the ISO13485 audit certificate from the independent auditors.

Key terms of the Agreement:

- The Agreement is to commence 1 October 2021. There are no conditions precedent to the Agreement.
- The Agreement is for exclusive sales into Australia, New Zealand and the Pacific Islands.

¹ The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19

² ASX 17 May 2021- AnteoTech signs manufacturing contract with Operon

- The initial term of the distribution agreement is for a period of five years, extendable by an additional three years on mutual agreement.
- In addition to the terms and conditions outlined in this announcement, the Agreement is subject to the standard terms, conditions, and warranties typical of a contract of this type. AnteoTech has the right to terminate the Agreement with immediate effect upon the breach or non-observance of any of the terms and conditions contained in the Agreement.

AnteoTech has sufficient test kit manufacturing capacity from its contract manufacturer Operon, in Spain, to meet immediate demand. Further demand is expected to be met by AnteoTech's internal manufacturing capacity, which is being developed and is planned to be available by Q1/ 2022³.

AnteoTech CEO Derek Thomson said, "We are excited to be working with fellow Queensland company Abacus to bring our EuGeni Reader and COVID-19 RDT to the market. The Australian Federal Government has flagged that rapid testing is likely to be an element of the process to reopen international borders. This change in stance is an important reason to accelerate our business development activity in Australia.

We have already received strong interest from the private sector for COVID-19 screening opportunities domestically and in the Pacific and we will be working with Abacus over the coming months to further promote EuGeni in these settings.

Our home markets of Australia, New Zealand and the Pacific Islands are small yet important parts of our rollout strategy. The partnership with Abacus will extend our reach and capability for those markets. In addition, we are seeing significant opportunities in Europe and Asia and are focusing most of our internal efforts on these regions given the potential these markets offer and the challenges with COVID most are still facing."

"As an Australian-based business, it is fantastic to see local investment in game-changing products such as EuGeni. Abacus dx has been distributing pathology testing solutions for over 50 years with product being imported from the US and Europe. Working with a local manufacturer, particularly one based in Brisbane, makes us very proud. AnteoTech have developed a product that will play a role in the COVID pandemic and beyond. Abacus dx is well positioned to develop the local market for EuGeni and support its growth. We are excited about the future developments of the EuGeni test menu and look forward to partnering with AnteoTech to launch EuGeni in Australia and New Zealand" said Shayne Christensen, CEO of Abacus dx.

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT ABACUS DX

Abacus dx is a distributor of diagnostic pathology, medical research, and innovative laboratory equipment solutions to a range of healthcare practitioners. Its customers include private and public laboratories, blood donor centres as well as university research departments. Abacus was acquired by Diploma PLC an international group of businesses supplying specialised technical products and services, in 2020. <https://www.abacusdx.com>

³ ASX 24 May 20201 – EuGeni Test Strip Manufacturing Strategy

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit www.anteotech.com

